Market Research Logo

The Next Wave In Cancer Treatment - Kinase Inhibitors

This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including:

  • Breast
  • Colorectal
  • Head/Neck
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Ovarian
  • Pancreatic
  • Prostate
  • Stomach
The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar and unit sales for each product.

The report includes statistical information for relevant cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. The market segments provide an overview, description of kinase inhibitors currently on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the cancer industry as a whole.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2012. Historical data was provided for the years 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.

The market for kinase inhibitors is heating up. The newer segment has shown strong growth throughout the 2000s with average annual increases of nearly 17%. Although the market is becoming more established and several billion dollar drugs have emerged this segment has enormous room for growth. The potential market is expected to grow to reach almost $20 billion worldwide within the next five years. Several factors continue to influence the double-digit growth this market has experienced, including the continued success of targeted therapy in cancer treatment, rising incidence of cancer, and increased cost for newly approved therapies in the advanced treatment area.

This market report only includes estimates and forecasts for the kinase inhibitor market for cancer indications. For a complete report on the cancer segment see Kalorama Information report Cancer Therapeutics and for an in-depth look at the new cancer vaccine segment see Kalorama Information report Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis.


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF THE MARKET
      • Table World Cancer Kinase Inhibitor Market, 2007-2017 (in millions of dollars at the manufacturer's level)
    • ISSUES AND TRENDS AFFECTING MARKET
    • LEADING COMPETITORS
  • Introduction
    • WHAT IS CANCER?
      • Biochemistry of Cancer Cells
      • Carcinogen Metabolism
      • Causes of Cancer Growth
        • Table Viruses Associated with Cancer in Humans
      • Cellular Oncogenes
      • Tumor Suppressor Genes
    • HISTORY AND GROWTH OF THE CANCER TREATMENT MARKET
    • INDUSTRY STRUCTURE
    • DEMOGRAPHICS AND STATISTICS
      • Global Cancer Statistics
        • Table Total Cancer Incidence by Gender and Country, 2010 Estimates
      • Lung Cancer
      • Breast Cancer
      • Colon/Rectal Cancer
        • Table World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both genders
        • Table Most Common Cancer by Region and Gender
      • Cancer Stats in the United States
        • Table United States: Total Cancer Incidence by Gender, 2012 Estimates
        • Table United States: Total Cancer Deaths by Gender, 2012 Estimates
      • Demographics
        • Table World Population by Selected Geographical Region, 2010 - 2050
      • Aging Population
        • Table Percent Population Over 65 by Year and Region, 2010-2050
    • LIFE EXPECTANCY AND CANCER
      • Life Expectancy
        • Table Average Life Expectancy in Years by Country 1980 and 2011
        • Table United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2009
        • Table United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2009
      • Birth Rates
        • Table Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
    • DESCRIPTION OF SELECT CANCERS
      • Breast Cancer
      • Colorectal Cancer
      • Head and Neck
      • Kidney
      • Leukemia
        • Table Types of Leukemia
      • Liver
      • Lung Cancer
        • Table Types of Primary Lung Cancer
      • Melanoma
        • Table Malignant Conditions of the Skin
      • Ovarian Cancer
      • Pancreas
      • Prostate Cancer
      • Stomach Cancer
  • Products
    • OVERVIEW
      • Bosulif (bosutinib)
      • Caprelsa (vandetanib)
      • Gleevec (imatinib)
      • Inlyta (axitinib)
      • Iressa (gefitinib)
      • Jakafi (ruxolitinib)
      • Nexavar (sorafenib)
      • Sprycel (dasatinib)
      • Stivarga (regorafenib)
      • Sutent (sunitinib)
      • Tarceva (erlotinib)
      • Tasigna (nilotinib)
      • Tyverb/Tykerb (lapatinib)
      • Votrient (pazopanib)
      • Xalkori (crizotinib)
      • Zelboraf (vemurafenib)
        • Table Cancer Indicated Kinase Inhibitor Approvals by Year
        • Table Leading Products by Sales, 2010 and 2012
  • Market Size and Growth
    • MARKET SUMMARY
      • Table World Cancer Kinase Inhibitor Market, 2007-2017 (in millions of dollars at the manufacturer's level)
      • Table World Cancer Kinase Inhibitor Market Estimated Distribution of Sales by Cancer Type, 2012 (in millions of dollars at the manufacturers level)
      • Markets by Geographical Segments
        • Table U.S. Kinase Inhibitor Products by Sales, 2012
      • Europe Market
        • Table Europe Kinase Inhibitor Products by Sales, 2012
      • Japan Market
      • ROW Market
    • COMPETITIVE ANALYSIS
      • Table Top 5 Suppliers: Cancer Kinase Inhibitor Market - Shares by Market Revenues, 2012 (in millions of dollars at the manufacturers level)
  • New Developments
    • THE PIPELINE FOR KINASE INHIBITORS
      • Table Developments in Kinase Inhibitors, Selected Projects
      • Significant Developments
      • Axitinib
      • Bosutinib
      • Cabozantinib
      • Crizotinib
      • Motesanib
      • Ponatinib
      • Regorafenib
      • Tivozanib
    • RECENT NDAACTIVITY
      • Table Recent NDA Activity: January 2011-October 2012
    • NEW APPROVALS
      • Table Select New Approvals (NCE, Indications, Dosage, Formulations) January 2010-October 2012
    • PATENT ACTIVITY AND GENERIC DEVELOPMENT
      • Table Patent Data for Kinase Inhibitors
  • Issues and Trends Affecting the Cancer Market
    • INTRODUCTION
    • INSURANCE AND REIMBURSEMENT ISSUES
    • PERSONALIZED MEDICINE
    • TARGETED CANCER THERAPY
    • PHARMACOGENOMICS
    • ALLIANCES ACQUISITIONS AND LICENSING AGREEMENTS
      • Amgen
      • Astellas
      • AstraZeneca
      • Bristol-Myers Squibb
      • Eli Lilly & Co.
      • Johnson & Johnson
      • Merck
      • Novartis
      • Pfizer
    • PATIENT-REPORTED OUTCOMES
    • HEALTHY LIFESTYLES CONTINUE TO SHOW PROMISE FOR CANCER PREVENTION
      • Obesity in the U.S.
        • Table Obesity Rates by U.S. State, 2011
      • U.S. Obesity Rates Differ Among Ethnic Groups
      • Alcohol's Affect on Cancer Incidence
    • MARKETING AND DISTRIBUTION TRENDS
    • GEOGRAPHICAL TRENDS
      • United States
      • Europe
      • Japan
    • ELDERLY CLINICAL TRIAL INVOLVEMENT
  • Company Profiles
    • INTRODUCTION
    • ASTRAZENECA PLC
    • BAYER
    • BRISTOL-MYERS SQUIBB COMPANY
    • GLAXOSMITHKLINE
    • NOVARTIS
    • PFIZER, INC.
    • ROCHE
  • Major Competitors' Addresses

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report